<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00955162</url>
  </required_header>
  <id_info>
    <org_study_id>BU0902</org_study_id>
    <nct_id>NCT00955162</nct_id>
  </id_info>
  <brief_title>Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France (&quot;RIME&quot;)</brief_title>
  <acronym>RIME</acronym>
  <official_title>A Multicentre, Randomised, Open-label, Active-controlled Trial of the Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indivior Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indivior Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who admit to using buprenorphine by the intravenous route will be randomized to
      either Subutex or Suboxone and be followed up for 3 months to determine if there is less
      injection with Suboxone than with Subutex based primarily on patient diaries.

      Patients randomized to Suboxone may continue to receive the product for a further 9 months at
      their request and will be monitored at 3 month intervals.

      Patients will receive a payment for the inconvenience of keeping a daily diary and to cover
      their travel expenses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of study drug injections per week</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Addiction severity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal severity</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Opioid Dependency</condition>
  <arm_group>
    <arm_group_label>Subutex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Suboxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine (Subutex)</intervention_name>
    <description>Sublingual tablet</description>
    <arm_group_label>Subutex</arm_group_label>
    <other_name>Subutex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine/naloxone (Suboxone)</intervention_name>
    <description>Sublingual tablet</description>
    <arm_group_label>Suboxone</arm_group_label>
    <other_name>Suboxone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female opioid-dependent outpatient aged 18 years or older,

          2. Women of childbearing potential must have a negative urine pregnancy test result at
             the Inclusion Visit (test under supervision of the investigator or designee),

          3. Women of childbearing potential must use an effective birth control method. Women of
             non-childbearing potential must be postmenopausal or must be surgically sterile
             (hysterectomy and/or bilateral oophorectomy),

          4. On buprenorphine (Subutex® or generic buprenorphine) maintenance therapy at a minimum
             daily dose of 2 mg for at least 3 months prior to inclusion,

          5. Declaring buprenorphine intravenous misuse at least four times/week and showing needle
             marks,

          6. Willing to stop or reduce buprenorphine intravenous misuse,

          7. Having received oral and written information about the trial, and provided written
             informed consent prior to admission to this trial.

        Exclusion Criteria:

          1. Pregnancy or breast-feeding,

          2. Contraindication or history of hypersensitivity to buprenorphine, naloxone or to any
             excipient of Suboxone® or Subutex®,

          3. Any medical or psychiatric condition which in the opinion of the investigator would
             make participation difficult or unsafe,

          4. Participating in another trial,

          5. Patients in the exclusion period of the &quot;Fichier National des personnes qui se prêtent
             à des recherches biomédicales&quot; (National Index of persons participating in biomedical
             researches, or National Index of volunteers).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier TOUZEAU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Paul Guiraud, Bagneux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Csst Antibes</name>
      <address>
        <city>Antibes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Paul Guiraud</name>
      <address>
        <city>Bagneux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cssa Bizia</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Carreire , CH Charles Perrens</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand, Centre Méthadone</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'addictologie, Hopital de Dole</name>
      <address>
        <city>Dole</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSST NAUTILIA (Ex Alinea)</name>
      <address>
        <city>Le Havre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSST Le Cèdre Bleu</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Esquirol - Intersecteur, Regional Soins en Addictologie</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Baudelaire</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csst de Montauban</name>
      <address>
        <city>Montauban</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSST Centre Hospitalier</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSST Logos</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Caremeau</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csst Espace Murger</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Anne</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre L'Envol (Csst)</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Baudelaire</name>
      <address>
        <city>Thionville</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Joseph Ducuing</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSST Centre Port Bretagne CH Charles Perrens</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2009</study_first_submitted>
  <study_first_submitted_qc>August 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2009</study_first_posted>
  <last_update_submitted>November 28, 2012</last_update_submitted>
  <last_update_submitted_qc>November 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Substance Abuse, Intravenous</keyword>
  <keyword>Buprenorphine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

